FIELD: medicine. SUBSTANCE: method involves separating formed elements from patient blood and intravenously introducing separated autoplasma. 5-7 cytopheresis sessions are carried out with 4-6 days long pause. Then, recombinant human erythropoietin is subcutaneously administered to the patient during 10-15 weeks at a dose of 25 mg/kg of body weight twice a week. EFFECT: enhanced effectiveness of treatment. 2 tbl
Authors
Dates
2002-07-27—Published
2000-01-31—Filed